Exploring Cordycepin as a Neuroprotective Agent in Huntington's Disease: In Vitro and In Vivo Insights

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a mutation in the Huntingtin (HTT) gene.
• Current treatments for HD are limited, highlighting the need for novel therapeutic strategies.
• Cordyceps sinensis and its compound cordycepin have demonstrated neuroprotective properties in other neurodegenerative conditions.

Purpose of the Study:

• To investigate the neuroprotective potential of cordycepin in cellular and animal models of Huntington's disease.
• To evaluate the effects of cordycepin on cell survival, mutant Huntingtin (HTT) aggregation, and neuronal function in HD.
• To assess the impact of cordycepin on disease progression markers, including body weight and protein aggregates, in an HD mouse model.

Main Methods:

• In vitro studies utilizing HD cell models to assess cordycepin's effects on cell viability and HTT aggregation.
• In vivo experiments involving R6/2 HD transgenic mice treated with cordycepin.
• Evaluation of body weight, pathological aggregates, and behavioral changes in treated mice.

Main Results:

• Cordycepin treatment improved cell survival and neuronal formation in HD cell models.
• A slight reduction in mutant HTT aggregates was observed in both in vitro and in vivo models.
• Mice treated with cordycepin showed a modest increase in body weight, but no significant behavioral improvements were noted.

Conclusions:

• Cordycepin exhibits neuroprotective effects and can reduce mutant protein aggregates in HD models.
• While not a standalone cure, cordycepin shows potential as an adjunctive therapy for Huntington's disease.
• Further investigation into the mechanisms underlying cordycepin's effects is warranted.